FN2 Earnings Intelligence

Ascendis Pharma A/S earnings overview

Latest Ascendis Pharma A/S (ASND) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportAscendis Pharma A/S reports Wednesday, Nov 11, 2026 · Before market openConsensus EPS $1.13 · consensus revenue $479.5M
ASND FY2026 Q2 · Calendar Q3 2026

Ascendis Pharma A/S

The quarter supports a constructive operating thesis: demand for Ascendis's rare-endocrine products is accelerating, YUVIWEL is creating expansion beyond switches, and the company has substantial cash to fund pipeline and geographic growth. The main counterweights are regulatory and litigation uncertainty, titration execution, and reliance on early U.S. growth.

EPS surprise+92.4%
Market move-3.6%

Get the ASND recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.